Connectivity Mapping Identifies BI-2536 as a Potential Drug to Treat Diabetic Kidney Disease
- 16 October 2020
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 70 (2), 589-602
- https://doi.org/10.2337/db20-0580
Abstract
Diabetic kidney disease (DKD) remains the most common cause of kidney failure, and the treatment options are insufficient. Here, we used a connectivity mapping approach to first collect 15 gene expression signatures from 11 DKD-related published independent studies. Then, by querying the Library of Integrated Network-based Cellular Signatures (LINCS) L1000 data set, we identified drugs and other bioactive small molecules that are predicted to reverse these gene signatures in the diabetic kidney. Among the top consensus candidates, we selected a PLK1 inhibitor (BI-2536) for further experimental validation. We found that PLK1 expression was increased in the glomeruli of both human and mouse diabetic kidneys and localized largely in mesangial cells. We also found that BI-2536 inhibited mesangial cell proliferation and extracellular matrix in vitro and ameliorated proteinuria and kidney injury in DKD mice. Further pathway analysis of the genes predicted to be reversed by the PLK1 inhibitor was of members of the TNF-α/NF-κB, JAK/STAT, and TGF-β/Smad3 pathways. In vitro, either BI-2536 treatment or knockdown of PLK1 dampened the NF-κB and Smad3 signal transduction and transcriptional activation. Together, these results suggest that the PLK1 inhibitor BI-2536 should be further investigated as a novel therapy for DKD.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK078897, R01DK088541, R01DK109683)
- Veterans Affairs (IBX000345C, R01DK117913-01)
This publication has 61 references indexed in Scilit:
- Enrichr: interactive and collaborative HTML5 gene list enrichment analysis toolBMC Bioinformatics, 2013
- NCBI GEO: archive for functional genomics data sets—updateNucleic Acids Research, 2012
- Transforming Growth Factor-β, Bioenergetics, and Mitochondria in Renal DiseaseSeminars in Nephrology, 2012
- Systems biology of kidney diseasesKidney International, 2012
- Defining human diabetic nephropathy on the molecular level: Integration of transcriptomic profiles with biological knowledgeReviews in Endocrine and Metabolic Disorders, 2008
- The Role of Inflammatory Cytokines in Diabetic NephropathyJournal of the American Society of Nephrology, 2008
- The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1Current Biology, 2007
- BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In VivoCurrent Biology, 2007
- The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and DiseaseScience, 2006
- Polo-like kinases and the orchestration of cell divisionNature Reviews Molecular Cell Biology, 2004